What is the purpose of this trial?
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.
Dates: 11/29/2017 - 01/31/2018
Last Updated: 11/30/2017
Study HIC#: 2000021520